)
Edge31 Oct 2025
Rolls-Royce: Full Thrust Ahead
From century-old crafted perfection to pandemic shock and reset, Rolls-Royce's story is shaped by heritage, turbulence, and a disciplined climb back.
Inhibikase Therapeutics (IKT) investor relations material
Inhibikase Therapeutics Q2 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2025 earnings summary14 Aug, 2025
Executive summary
Advanced IKT-001, a prodrug of imatinib, for PAH with Phase 2b IMPROVE-PAH trial set to begin in H2 2025, enrolling ~150 participants and testing two doses versus placebo.
Discontinued and outlicensed the Parkinson's disease program (risvodetinib/IkT-148009).
Completed CorHepta Pharmaceuticals acquisition, resulting in a $7.4M IPR&D expense and $1.0M stock-based compensation.
Raised $99.6M in net proceeds from an October 2024 private placement, with additional warrant financing potential.
Ended the quarter with $87.7M in cash, cash equivalents, and marketable securities.
Financial highlights
Net loss of $9.9M for Q2 2025 ($0.11/share), up from $5.0M in Q2 2024; six-month net loss $23.6M ($0.26/share), up from $9.6M year-over-year.
R&D expenses rose 71% year-over-year to $5.3M for Q2 2025, including a $7.4M IPR&D write-off and $1.0M stock-based compensation from CorHepta.
SG&A expenses increased 200% year-over-year to $5.9M for Q2 2025, including $1.0M in severance from executive transitions.
Interest income increased to $916,755 in Q2 2025 from $90,927 in Q2 2024.
No revenue recognized for the period.
Outlook and guidance
Cash and marketable securities expected to fund operations for at least the next twelve months.
Phase 2b IMPROVE-PAH trial to initiate in H2 2025, with significant R&D investment anticipated.
Additional funding may be sought through equity, debt, or collaborations; future losses expected as development continues.
When will IMPROVE-PAH study be initiated?
Explain the increase in SG&A expenses.
IKT-001 dosage vs. imatinib exposure?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Inhibikase Therapeutics earnings date
Q3 202513 Nov, 2025
Next Inhibikase Therapeutics earnings date
Q3 202513 Nov, 2025
The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Inhibikase Therapeutics Inc. is a biopharmaceutical company focused on developing treatments for neurodegenerative diseases and cancers. The company’s research primarily targets diseases related to protein misfolding, such as Parkinson's disease, by aiming to inhibit the malfunction of key cellular processes. Inhibikase Therapeutics develops therapeutics that aim to modify the progression of these diseases and improve patient outcomes. Its approach includes addressing both neurological and oncological conditions through small-molecule therapeutics. The company is headquartered in Atlanta, Georgia, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage